Ctrl

K

Bendamustine

Class
DNA crosslinking agents
Subclass
Alkylating agents
Generic name
Bendamustine hydrochloride
Brand names
Treanda®
Common formulations
Concentrate for injectable solution
Dosage and administration
Adults patients
Treatment of chronic lymphocytic leukemia
•
100 mg/m² IV × 1 on day 1 of therapy and another dose on day 2 of therapy, of a 28-day cycle, for up to 6 cycles
Other off-label uses
•
Adjunctive treatment for chronic lymphocytic leukemia
Indications for use
Labeled indications
Adults
•
Treatment of chronic lymphocytic leukemia
•
Treatment of indolent B-cell non-Hodgkin lymphoma
Off-label indications
Adults
•
Adjunctive treatment for chronic lymphocytic leukemia
Safety risks
Boxed warnings
Exacerbation of kidney disease
•
Use extreme caution with mild or moderate renal impairment.
Contraindications
A known hypersensitivity reaction to bendamustine
Warnings and precautions
Anaphylactoid reactions
•
Use caution risk factors for Infusion-related reactions.
Infections
•
Use caution with myelosuppression.
Progressive multifocal leukoencephalopathy
•
Use caution with new or worsening neurological, cognitive, or behavioral signs or symptoms.
Reactivation of HBV infection
•
Use caution with mild hepatic disease/impairment.
Skin infections
•
Use caution who receive allopurinol with bendamustine.
Specific populations
Renal impairment
eGFR 20-50 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
eGFR 10-20 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
eGFR < 10 mL/min/1.73 m²
•
Use with caution.
Renal replacement therapy
Continuous renal replacement
•
Use acceptable. No dose adjustment required.
Intermittent hemodialysis
•
Use with caution. Dose as in eGFR < 10 mL/min/1.73 m².
Peritoneal dialysis
•
Use with caution. Dose as in eGFR < 10 mL/min/1.73 m².
Hepatic impairment
Child-Pugh A (mild)
•
Use with caution. Monitor serum aminotransferases.
Child-Pugh B (moderate)
•
Do not use.
Child-Pugh C (severe)
•
Do not use.
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: D
•
Avoid use. Evidence of fetal harm in humans. Females of reproductive potential should avoid pregnancy during and after bendamustine therapy. Advise pregnant women of the potential risk to the fetus.
Breastfeeding
Little information available on breastfeeding safety.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
Anemia, ↓ WBC count, ↓ blood lymphocyte count, ↓ platelet count, neutropenia, chills, dizziness, dyspepsia, headache, insomnia, somnolence
Common 1-10%
•
Anaphylactoid reactions, DRESS syndrome, ↓ serum calcium, ↓ serum potassium, ↓ serum sodium, dehydration, dysgeusia, gastroesophageal reflux, hyperhidrosis, hypertension, hypertensive crisis, hypotension, ↑ blood glucose, ↑ liver enzymes, ↑ serum TBIL, ↑ serum uric acid, peripheral edema, pharyngitis, abdominal pain, anorexia, anxiety, arthralgia, asthenia, back pain, bone pain, chest pain, constipation, cough, depression, diarrhea, dry mouth, dyspnea, fatigue, fever, itching, nasal congestion, nausea, night sweats, skin rash, vomiting, weight loss, skin dryness, Stevens-Johnson syndrome, stomatitis, tachycardia, toxic epidermal necrolysis
Unknown frequency
•
Atrial fibrillation, azoospermia, bullous pemphigoid, contact dermatitis, erythema multiforme, gangrene, heart failure, hemolysis, hepatitis, leukemia, malignancy, myocardial infarction, pancytopenia, phlebitis, pneumonitis, progressive multifocal leukoencephalopathy, pulmonary fibrosis, renal failure, infertility, injection site reactions, palpitations, skin cancer, spermatogenesis, tumor lysis syndrome, wheezing
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource